Company intelligence / Profile preview

Eitr Biologics

San Diego, California, United States

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Eitr Biologics develops next-generation single domain antibody-based immunotherapeutics using its proprietary ODIN platform. Their lead molecules are designed to enhance tumor penetration and immune synapse formation for oncology applications, as well as to target difficult-to-reach bacterial and viral infections. No published clinical results yet; the company appears to be in preclinical development

Therapeutic areas: OncologyInfectious Diseases
Modalities: Single domain antibodies (including bispecifics)nanotherapeutics
Industry: Biotech

Drug pipeline

2 assets

RBT-0813

Pre-clinical

Indications: COVID-19

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Eitr Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eitr Biologics.

Explore the full profile